I work in the Research Development team at the MND Association as a Research Co-ordinator. I completed my undergraduate degree in Biomedical Science and I became very interested in neuroscience throughout my degree. Following on from this, I did a Master’s degree in Molecular Medicine, with a focus on gene therapies. As part of my role, I will be helping the Research Development team to identify interesting updates in MND research and communicate these via the blog in an understandable and engaging way.
Reading Time: 7 minutes Researchers from the University of Aberdeen and the University of Edinburgh have developed a new tool that could help to detect signs of MND in cells before symptoms of the disease start. This work was recently published and was previously presented at the 34th International Symposium in Basel by Dr Jenna Gregory. The new tool…
Reading Time: 7 minutes Each year the 11th of February sees the world recognise and celebrate the contributions of women in science. The International day of Women and Girls in science was established by the United Nations to promote gender equality and encourage more women and girls across the world to aim to build a career in science. It…
Reading Time: 9 minutes Research into genetic causes of MND has greatly increased over the last few decades and gene changes have since been found to play a role in both inherited and non-inherited (sporadic) forms of the disease. Since the discovery of the first gene change in MND around 30 years ago, researchers have found over 40 gene…
Reading Time: 7 minutes Each year we host the International Symposium on ALS/MND in December and this is the largest medical and scientific conference specific to MND. The 34th Symposium was held in Basel, Switzerland from the 6th to 8th December and over 1300 people attended from over 48 different countries to share the latest MND research updates, connect…
Reading Time: 7 minutes Each year we invite plenary speakers who are experts in their fields to provide an overview on topics across MND research and clinical practice. This year we have 14 plenary speakers talking about ALS/MND who will discuss a wide range of topics from genetics to tissue biomarkers to improving clinical practice. In this second blog we will be taking a closer look at some of our plenary speakers this year and sharing more about the topics they will be discussing.
Reading Time: 7 minutes As the research team count down to this year’s International Symposium on ALS/MND, we will be posting blogs throughout November to give you a snapshot of some of the research being presented at this year’s event. This year marks the 34th Symposium, the largest scientific and medical conference specific to ALS/MND, and we are looking…
Reading Time: 6 minutes MND is a very complex disease and collaboration within the research community is key to building on our current understanding of the disease biology and finding effective treatments. The MND Association recognises the importance of expanding the dedicated MND research workforce, as well as supporting those who are already working in the field. To fund…
Reading Time: 6 minutes QurAlis, a biotechnology company focused on developing precision medicines for MND and other neurodegenerative diseases, has announced the opening of a clinical trial in the UK. This trial of a gene therapy, called QRL-201, is a phase 1 trial in people with MND and will test the therapy to determine whether it is safe and…
Reading Time: 5 minutes The MND clinical trial landscape has grown vastly over the last decade and this has led to increased opportunities for people with MND to take part in research across the globe. Behind these trials, sit a large number of highly dedicated staff at each trial site who make sure the trial is set-up, recruiting and…
Reading Time: 6 minutes MND is a very complex disease, and in the UK there is still only one approved treatment so the need for more effective treatments remains at the forefront of MND research. There have been over 140 clinical trials for MND over the last several decades and the majority of these have, unfortunately, not led to…
